[What's new in the management of systemic sclerosis].

Several human studies show positive signals, while research methods and sample sizes continue to develop.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

This review of the literature highlights the results of the recent randomized controlled trials about the management of systemic sclerosis (SSc) and its complications. The latest randomized studies have failed to demonstrate the utility against placebo of the injections of botulinum toxin A to achieve a better control of Raynaud's phenomenon and the efficacy of the adipose-derived cell transplantation for the treatment of hand dysfunction. Rituximab allows a significant improvement of cutaneous induration. The injections of mesenchymal stromal cells are well tolerated and should encourage future randomized trials to evaluate their efficacy. Finally, nintedanib and tocilizumab allow a reduction in the rate of decline of lung function, as well as a possible stabilization with tocilizumab. Cet article expose les résultats des essais randomisés et contrôlés récents concernant la prise en charge de la sclérodermie systémique (SSc) et ses complications. Les études discutent l’utilité des injections de la toxine botulinique pour le contrôle du phénomène de Raynaud, et des injections de cellules dérivées du tissu adipeux pour améliorer la fonctionnalité de la main. Le rituximab permet une amélioration significative de l’induration cutanée, et les injections de cellules stromales mésenchymateuses, en plus d’être bien tolérées, ouvrent la voie à d’éventuels essais randomisés en vue d’éva

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.